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Abstract: A growing body of evidence suggests that oxidative stress-mediated cell death signaling mechanisms may exert 
neurotoxic effects of methamphetamine (MA)-induced dopaminergic neuronal loss. However, the means by which oxida-
tive stress induced by MA causes neurodegeneration remains unclear. In recent years, resveratrol has garnered consider-
able attention owing to its antioxidant, anti-inflammatory, anti-aging, and neuroprotective properties. In the present   
study, we sought to investigate the neuroprotective effects of resveratrol against apoptotic cell death in a mesencephalic 
dopaminergic neuronal cell culture model of MA neurotoxicity. MA treatment in the N27 dopaminergic neuronal cell 
model produced a time-dependent activation of the apoptotic cascade involving caspase-3 and DNA fragmentation. We 
found that the caspase-3 activation preceded DNA fragmentation. Notably, treatment with resveratrol almost completely 
attenuated MA-induced caspase-3 activity, but only partially reduced apoptotic cell death. We conclude that the neuropro-
tective effect of resveratrol is at least in part mediated by suppression of caspase-3 dependent cell death pathways. Collec-
tively, our results demonstrate that resveratrol can attenuate MA-induced apoptotic cell death and suggest that resveratrol 
or its analogs may have therapeutic benefits in mitigating MA-induced dopaminergic neurodegeneration. 
Keywords: Resveratrol, drug abuse, neuroprotection, neurotoxicity, oxidative stress, apoptosis. 
INTRODUCTION 
  Methamphetamine (MA) is a psychostimulant that is 
widely abused in the US and worldwide [1]. Repeated use 
has been shown to be associated with euphoria, decreased 
appetite, increased alertness, and hyperthermia [2]. Several 
of these effects are believed to play a central role in the high 
abuse potential of MA, which causes not only severe health 
problems but also poor socioeconomic conditions for the 
abusers. MA use leads to functional alterations and neurode-
generative changes in various brain regions [3, 4]. Notably, 
decreased levels of tyrosine hydroxylase (TH) and dopamine 
transporter (DAT) immunoreactivity were measured in the 
striatum of MA users [5, 6]. Additionally, several studies 
have repeatedly demonstrated that in rodents MA causes 
long term neurodegenerative changes in dopaminergic and 
serotonergic nerve terminals in several brain regions, includ-
ing the cortex, striatum, and hippocampus [7-9]. The changes 
include long term reductions in striatal dopamine (DA) and 
serotonin (5-HT) levels, decreased tryptophan hydroxylase 
and tyrosine hydroxylase, loss of DA and 5-HT transporters, 
and associated neurodegenerative changes in the mono-
aminergic terminals [10]. The loss of DA transporters has 
been documented in abstinent MA users; this deficiency is 
believed to contribute to reduced motor function and memory 
impairments [11]. Furthermore, based on the similarities 
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between MA-induced dopaminergic neurodegenerative 
changes and PD-induced neuronal damage, MA has been 
used as a putative model for the study of dopaminergic   
terminal degeneration associated with Parkinsonism [12].  
  Although several mechanisms have been proposed to 
underlie MA-induced neurotoxicity, the exact mechanism 
remains unknown. Mounting evidence suggests that elevated 
oxidative stress may contribute to MA-induced degenerative 
changes. In fact, oxidative damage to proteins, lipids and 
DNA has been shown in the brains of MA-treated animals 
[13-15]. Accumulation of oxidative products may lead to 
activation of the apoptosis related cell death cascade.   
Increasing lines of evidence suggest that mitochondria-
dependent apoptotic signaling events may underlie neurode-
generative changes associated with MA-induced neurotoxic-
ity [16, 17]. Experimental evidence indicates that key events 
of MA-induced mitochondrial changes include membrane 
depolarization, Bcl2/Bax dysregulation, cytochrome C re-
lease, and capase-9 and -3 activation [18, 19]. Moreover, 
administration of antioxidants effectively attenuated key 
MA-induced mitochondrial dependent apoptotic changes, 
suggesting that oxidative stress plays a role in the neurotox-
icity [20-22]. 
  Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenolic 
phytoalexin found in the skin of red grapes, red wine, and 
other natural food sources such as nuts. Interestingly,   
resveratrol has been shown to possess a wide variety of bio-
logical and pharmacological effects, including antioxidant, 
anti-apoptotic, anti-inflammatory, anti-carcinogenic, and 
anti-aging properties [23-27] Furthermore, resveratrol has 50    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kanthasamy et al. 
been shown to attenuate neuronal death associated with 
MPP
+-induced oxidative stress [28-31]. However, currently 
there is no information available regarding the neuroprotec-
tive effects of resveratrol on MA-induced dopaminergic neu-
rodegenerative effects. Hence, we hypothesized that resvera-
trol may also protect dopaminergic neurons against MA-
induced neurotoxicity by modulating the caspase-3 depend-
ent apoptotic cell death pathway. Therefore, we evaluated 
possible neuroprotective properties of resveratrol in a well 
characterized cell culture model of MA -induced dopaminer-
gic neurotoxicity.  
MATERIALS AND METHODS 
Materials 
  Methamphetamine was obtained from the National Insti-
tute of Drug Abuse (NIDA) drug supply program. Caspase-3 
substrate, Ac-DEVD-AFC, was purchased from EMD Bio-
sciences, Inc. (Gibbs town, NJ). Cell Death Detection Elisa 
Plus Assay Kit was purchased from Roche Molecular Bio-
chemicals (Indianapolis, IN). All tissue culture supplies were 
purchased from Gibco-BRL (Gaithersburg, MD). Other rou-
tine laboratory reagents were purchased from Fisher Scien-
tific (Pittsburg, PA). The immortalized rat mesencephalic 
(N27) cell line was a kind gift of Dr. Kedar N. Prasad, Univ. 
of Colorado Health Sciences Center (Denver, CO). 
Cell Culture Model 
 Immortalized rat mesencephalic neuronal cells 
(1RB3AN27, commonly referred to as N27 dopaminergic 
cells) were grown in RPMI medium supplemented with 10% 
fetal bovine serum, 1% L-glutamine, penicillin (100 U/ml), 
and streptomycin (100 U/ml), and maintained at 37°C in a 
humidified atmosphere of 5% CO2 (Anantharam, 2002; 
Clarkson, 1999). We previously reported that N27 neuronal 
cells can be used as a model system to study the apoptotic 
changes associated with neurotoxicity of dopaminergic   
neurotoxicants such as methamphetamine and MPP+ [32-
34]. After 2-4 days in culture, N27 cells were harvested   
and resuspended in complete growth medium at a cell   
density of 1-3 x 10
6/ml. Cells were treated with 2 mM MA in  
the presence or absence of 10 M resveratrol for 12 or 24 hr. 
Following the treatments, cells were homogenized and the 
lysates were used for caspase-3 and DNA fragmentation   
assays. 
Measurement of Caspase-3 Activity 
  Caspase-3 activity was used as an early marker of apop-
tosis and was determined as previously described in our pub-
lications [35]. Briefly, cell lysates were then incubated at 
37°C for 20-30 min to allow complete lysis. Lysates were 
quickly centrifuged and cell-free supernatants were incu-
bated with 50 M Ac-DEVD-AFC (caspase-3 substrate) at 
37°C for 1 hr. Caspase activity was then measured by deter-
mining the formation of 7-amido-4-trifluoromethylcoumarin 
(AFC) resulting from caspase cleavage using a Biotek plate 
reader (excitation 400 nm, emission 505 nm). The fluores-
cence signals from the samples were normalized to protein 
concentration, which was measured by the Bradford protein 
assay. 
DNA Fragmentation Analysis 
  DNA fragmentation assay was performed using a Cell 
Death Detection Elisa Plus Assay Kit, as described in our 
publications [35, 36]. Briefly, 20 l aliquots of supernatant 
obtained from cell lysates were dispensed to streptavidin-
coated 96 well microtiter plates followed by addition of 80 
l of antibody cocktail. Plates were incubated for 2 hr at RT 
with mild shaking. The antibody cocktail consisted of a mix-
ture of anti-histone biotin and anti-DNA-HRP directed 
against various histones and antibodies to both single strand 
DNA and double strand DNA, which are major constituents 
of the nucleosomes. After incubation, unbound components 
were removed by washing with the incubation buffer   
supplied with the kit. Quantitative determination of the 
amount of nucleosomes retained by anti-DNA-HRP in the 
immunocomplex was conducted spectrophotometrically   
with ABTS as an HRP substrate (supplied with the kit). 
Measurements were made at 405 nm against an ABTS   
solution as a blank (reference wavelength ~490 nm) using  
a Biotek microplate reader. 
RESULTS 
Effects of Resveratrol on Methamphetamine-Induced 
Caspase-3 Activation  
  We previously demonstrated that caspase-3 activation is 
one of the key events in dopaminergic neurotoxicity caused 
by several neurotoxicants, including MA and MPP+ [32-34]. 
We also showed that caspase-3 activity can be used as a reli-
able marker for evaluation of neuroprotective efficacy of 
experimental pharmacological agents against diverse neuro-
toxicants [34-36]. Therefore, we first examined whether res-
veratrol attenuates MA-induced caspase-3 activation. As 
depicted in Fig. (1), treatment of N27 cells with 2 mM MA 
resulted in a significant increase (~130% increase; p<0.01) in 
caspase-3 activation as compared to the control group. How-
ever, cells that were pretreated with resveratrol for 1 hr prior 
to MA treatment showed significantly reduced caspase-3 







Fig. (1). Resveratrol protects against methamphetamine-induced 
caspase-3 activity in a dopaminergic neuronal cell model. N27 
dopaminergic neuronal cells were pretreated with 10 M resveratrol 
for 1 hr and then exposed to 2 mM methamphetamine (MA) for 12 
hr. Caspase-3 activity was measured using the caspase-3 specific 
substrate Ac-DEVD-AFC, as described in “Materials and Methods.” 
Each bar represents mean ± SEM from four individual measurements. 
*p<0.01, comparison of control vs. MA treatment. **p<0.01, com-
parison of MA vs. MA and resveratrol treatment. Neuroprotective Effect of Resveratrol Against Methamphetamine-Induced  Current Neuropharmacology, 2011, Vol. 9, No. 1    51 
alone treated group did not show any significant changes in 
caspase-3 activation as compared to the control. These re-
sults indicate that resveratrol can attenuate activation of key 
proapoptotic changes following MA treatment.  
Effects of Resveratrol on Methamphetamine -Induced 
DNA Fragmentation  
  In order to determine whether resveratrol protects against 
MA-induced neuronal apoptosis, we measured DNA frag-
mentation in resveratrol treated cells. As shown in Fig. (2), 
MA significantly increased DNA fragmentation following a 
24 hr treatment. The magnitude of increase in DNA frag-
mentation was about 2-fold in MA-treated cells as compared 
to the control group. We observed a significant reduction in 
DNA fragmentation in N27 cells pretreated with 10 uM res-
veratrol for 1 hr prior to MA treatment. In contrast, the res-
veratrol alone treated group did not have altered basal levels 
of DNA fragmentation. Collectively, these results demon-
strate that resveratrol protects against MA-induced apoptosis 










Fig. (2). Resveratrol attenuates methamphetamine-induced DNA 
fragmentation in a dopaminergic neuronal cell model. N27 dopa-
minergic neuronal cells were pretreated with 10 M resveratrol for 1 
hr and then exposed to 2 mM methamphetamine (MA) for 24 hr. 
DNA fragmentation was measured using the ELISA based cell death 
assay kit, as described in “Materials and Methods.” Each bar repre-
sents mean ± SEM from four individual measurements. *p<0.01, 
comparison of control vs. MA treatment. **p<0.01, comparison of 
MA vs. MA and resveratrol treatment. 
DISCUSSION 
  In the present study we examined the neuroprotective 
effects of a polyphenolic natural product, resveratrol, on 
MA-induced neurotoxicity. We show that pretreatment of 
mesencephalic dopaminergic cells with resveratrol conferred 
neuroprotection against MA-induced cell death. Specifically, 
resveratrol showed anti-apoptotic effects by blocking both 
caspase-3 activation and DNA fragmentation. Resveratrol 
treatment alone did not alter basal caspase-3 or DNA frag-
mentation, suggesting that low micromolar concentrations of 
the compound are not toxic to dopaminergic neuronal cells. 
To our knowledge, this is the first study demonstrating the 
neuroprotective efficacy of resveratrol against MA-induced 
neurotoxicity. 
  It is well known that MA causes long term neurodegen-
erative changes in dopaminergic and serotonergic nerve ter-
minals in several brain regions including cortex, striatum, 
and hippocampus [37-39]. Neurotoxic mechanisms impli-
cated in MA-induced neurodegneration include, mitochon-
drial dysfunction, oxidative stress, ER stress, and apoptosis. 
In fact, the critical contribution of oxidative stress related 
mechanisms in MA-induced dopaminergic neuronal degen-
eration has been described extensively, whereby accumula-
tion of oxidatively damaged lipids [40], proteins [14], and 
DNA [15] has been shown in various brain regions of ro-
dents as well as induction of oxidative stress mechanisms in 
in vitro dopaminergic cell culture models [10]. In addition, 
MA-induced displacement of DA from vesicles and subse-
quent buildup within the cytosolic and extracellular space 
and the resulting formation DA related oxidative product, 
quinone has been shown to be a critically involved in MA-
induced dopaminergic neurotoxicity [41, 42]. Moreover, 
inhibitors of dopamine synthesis or release can attenuate 
cellular toxicity in experimental models [43]. Previous stud-
ies have suggested that oxidative stress may be an early 
event in dopaminergic neurodegeneration since neurotoxicity 
is attenuated by antioxidants such as trolox [44, 45] and glu-
tathione (GSH) [43]. In a recent report, resveratrol inhibited 
ROS accumulation, depletion of GSH, and cellular oxidative 
damage following treatment with MPP+ as well as 6-OHDA, 
suggesting antioxidant factors are important neuroprotective 
effects of resveratrol [46-48]. Therefore, the contribution of 
antioxidant properties of resveratrol in preventing MA-
induced cell death cannot be discounted. 
  MA-induced oxidative stress is functionally linked to 
mitochondrial dependent apoptosis, which has been proposed 
to play a central role in mediating neurotoxicity [18, 38]. 
MA is a cationic lipophilic molecule that diffuses into mito-
chondria and is retained there, resulting in dissipation of the 
mitochondrial membrane potential and disturbance of mito-
chondrial biogenesis [17]. Additionally, MA causes in-
creases in pro-apoptotic proteins, namely Bax, Bad, and Bid, 
and decreases in anti-apoptotic proteins, Bcl-2 and Bcl-XL 
[18, 19]. Subsequently, release of mitochondrial cytochrome 
C, followed by activation of caspase-9 and -3, and break-
down of several proteins, including PARP, lamin, and DNA 
fragmentation factor 45 fragment (DFF-45) [18, 38] have 
been shown to participate in MA-induced apoptotic cell 
death. In this context, over-expression of Bcl-2 and inhibi-
tion of caspases confers resistance against MA-induced 
apoptotic cell death [10]. In the mitochondrial dependent 
apoptotic cascade, caspase-3 activation plays a central role in 
mediating DNA fragmentation, which ultimately leads to cell 
death [10, 18, 32, 38]. These studies underscore the impor-
tance of the mitochondrial mediated caspase cascade in MA-
induced neurotoxicity. In the present study, resveratrol pre-
treatment almost completely inhibited MA-induced caspase-
3 activation, but only partially inhibited MA-induced DNA 
fragmentation. These results suggest that MA-induced neuro-
toxicity is not entirely dependent on caspase-3 activation, 
and that other factors might play a role in the neurotoxicity. 
ER stress, ubiquitin dysfunction, and autophagic impairment 
may contribute to cell death. We recently reported that MA 
dramatically increases autophagy in a dopaminergic cell 
model [32], but the role of autophagy in MA-induced dopa-
minergic neuronal loss is currently being studied in our labo-
ratory. 52    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kanthasamy et al. 
  Recent studies have demonstrated that polyphenolic com-
pounds exert protective effects against DA associated 
oxidative damage in dopaminergic neurons both in in vivo 
and in vitro models of dopaminergic neuronal degeneration 
[48-50]. Resveratrol has multiple pharmacological proper-
ties: antioxidant, anti-inflammatory, cardioprotective and 
anti-aging properties [51]. Emerging studies indicate that 
resveratrol extends the lifespan via the sirtuin pathway [52]. 
Resveratrol’s antioxidant properties might be partly medi-
ated by increases in SOD and catalase activity [52]. Never-
theless, the antioxidant property alone cannot account for its 
neuroprotective effects. Resveratrol may activate cell spe-
cific signaling pathways that facilitate the activation of pro-
survival mechanisms and enable the maintenance of mito-
chondrial integrity, thereby attenuating the multiple cell sig-
naling pathways that cause cell death. Since multiple com-
plex mechanisms mediate neurodegenerative processes, 
pharmacological agents like resveratrol, with broad spectrum 
biochemical properties, may hold promise for use as neuro-
protective therapies. Pharmacological agents that target a 
specific mechanism often fail or are ineffective in clinical 
trials, possibly because of their narrow range of activity. 
  In summary, we demonstrate that resveratrol treatment is 
effective against the MA-induced apoptotic cell death proc-
ess involving activation of caspase-3 and DNA fragmenta-
tion. Elucidation of the underlying mechanism of resveratrol 
neuroprotection in MA-induced apoptotic cell death may 
improve understanding of the molecular basis of this poly-
phenolic compound. Evaluation of the molecular mecha-
nisms mediating the neuroprotective effects of resveratrol 
and other related polyphenols may lead to the development 
of novel therapies for the treatment of dopaminergic neu-
rodegenerative processes associated with drugs of abuse as 
well as chronic neurodegenerative disorders including Park-
inson’s disease. 
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